Studies have shown that the blockage of the interaction of SDF-1 with its receptor, CXCR4, by a clinical drug, AMD3100, enhanced the efficacy of RT in glioma [19], breast, and lung carcinoma [20] by preventing the recruitment of bone marrow-derived cells (BMDCs) and tumor revascularization. Here, CXCL12 is linked to neoplasm.